Edition:
India

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

4.13USD
25 Sep 2020
Change (% chg)

-- (--)
Prev Close
$4.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,720
52-wk High
$13.33
52-wk Low
$2.94

Latest Key Developments (Source: Significant Developments)

Bio-Path Updates Intellectual Property Portfolio With Addition Of Recently Issued Second Platform Technology Patent
Wednesday, 25 Sep 2019 

Sept 25 (Reuters) - Bio Path Holdings Inc ::BIO-PATH UPDATES INTELLECTUAL PROPERTY PORTFOLIO WITH ADDITION OF RECENTLY ISSUED SECOND PLATFORM TECHNOLOGY PATENT.BIO PATH HOLDINGS INC - UNITED STATES PATENT AND TRADEMARK OFFICE HAS ISSUED A PATENT WITH CLAIMS RELATED TO DNABILIZE.  Full Article

Bio-Path Holdings Reports Full Year 2018 Financial Results
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS.BIO PATH HOLDINGS INC - AS OF DECEMBER 31, 2018, COMPANY HAD CASH OF $1.0 MILLION, COMPARED TO $6.0 MILLION AT DECEMBER 31, 2017.BIO PATH HOLDINGS INC - ON TRACK TO SUBMIT OUR INVESTIGATIONAL NEW DRUG APPLICATION TO BEGIN A PHASE 1 STUDY OF OUR SECOND DRUG CANDIDATE, BP1002.  Full Article

Bio-Path Announces Clinical Update To Interim Analysis Of Phase 2 Prexigebersen Trial In Acute Myeloid Leukemia
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Bio Path Holdings Inc ::BIO-PATH ANNOUNCES CLINICAL UPDATE TO INTERIM ANALYSIS OF PHASE 2 PREXIGEBERSEN TRIAL IN ACUTE MYELOID LEUKEMIA.BIO PATH HOLDINGS INC - INTERIM DATA UPDATE FROM PHASE 2 STUDY DEMONSTRATES MEANINGFUL CLINICAL IMPROVEMENT WITH EXCELLENT PATIENT SAFETY PROFILE.BIO PATH HOLDINGS INC - COMPANY PROVIDES CLINICAL DEVELOPMENT PLAN WITH PATHWAYS TO REGISTRATION.BIO PATH HOLDINGS INC - PATH INTENDS TO FILE FOR REGISTRATION OF BP1002 FOR TREATMENT OF VENETOCLAX RELAPSES IN BOTH CLL PATIENTS AND AML PATIENTS.  Full Article

Bio-Path Announces Clinical Update To Interim Analysis Of Phase 2 Prexigebersen Trial In Acute Myeloid Leukemia
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Bio Path Holdings Inc ::BIO-PATH ANNOUNCES CLINICAL UPDATE TO INTERIM ANALYSIS OF PHASE 2 PREXIGEBERSEN TRIAL IN ACUTE MYELOID LEUKEMIA.BIO PATH HOLDINGS INC - INTERIM DATA UPDATE FROM PHASE 2 STUDY DEMONSTRATES MEANINGFUL CLINICAL IMPROVEMENT WITH EXCELLENT PATIENT SAFETY PROFILE.BIO PATH HOLDINGS INC - COMPANY PROVIDES CLINICAL DEVELOPMENT PLAN WITH PATHWAYS TO REGISTRATION.BIO PATH-INTENDS TO FILE FOR REGISTRATION OF BP1002 FOR TREATING VENETOCLAX RELAPSES IN BOTH CLL PATIENTS & AML PATIENTS .  Full Article

Bio-Path Holdings Announces 1-For-20 Reverse Stock Split
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS ANNOUNCES 1-FOR-20 REVERSE STOCK SPLIT.BIO PATH- AS RESULT OF REVERSE STOCK SPLIT, EVERY 20 SHARES OF COMMON STOCK ISSUED AND OUTSTANDING WERE CONSOLIDATED INTO 1 ISSUED AND OUTSTANDING SHARE.REVERSE STOCK SPLIT REDUCED CO’S ISSUED AND OUTSTANDING SHARES OF COMMON STOCK FROM ABOUT 22.2 MILLION TO ABOUT 1.1 MILLION.  Full Article

Bio-Path Holdings Announces Pricing Of Public Offering Of Common Stock
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 8.6 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $0.13 PER SHARE.BIO-PATH EXPECTS TO RECEIVE AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $1.1 MILLION FROM OFFERING.  Full Article

Bio Path Holdings Inc Says Board Approved Ratio For Reverse Stock Split Of 1-For-20
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Bio Path Holdings Inc ::BIO PATH HOLDINGS INC - ON JANUARY 11, 2019, BOARD OF DIRECTORS APPROVED A RATIO FOR REVERSE STOCK SPLIT OF 1-FOR-20.  Full Article

Bio-Path Holdings Inc Announces Proposed Public Offering Of Common Stock
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

BRIEF-Bio Path On July 2, Delivered Written Notice To Cantor Fitzgerald That It Had Elected To Terminate Sales Agreement Effective As Of July 12, 2020

* BIO PATH - ON JULY 2,DELIVERED WRITTEN NOTICE TO CANTOR FITZGERALD THAT IT HAD ELECTED TO TERMINATE SALES AGREEMENT EFFECTIVE AS OF JULY 12, 2020